CARM Carisma Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CARM

Price (delayed)

$1.62

Market cap

$67.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.59

Enterprise value

-$7.18M

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is ...

Highlights
The company's EPS has surged by 91% YoY and by 76% QoQ
The company's revenue has surged by 52% YoY and by 3.9% QoQ
The equity has soared by 117% YoY but it is down by 43% QoQ
The debt has plunged by 92% YoY but it has grown by 14% from the previous quarter
The net income has declined by 42% year-on-year and by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sesenbio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CARM
Market
Shares outstanding
41.54M
Market cap
$67.3M
Enterprise value
-$7.18M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.46
Price to sales (P/S)
3.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.48
Earnings
Revenue
$14.92M
EBIT
-$88.82M
EBITDA
-$80.55M
Free cash flow
-$82.31M
Per share
EPS
-$2.59
Free cash flow per share
-$2.46
Book value per share
$0.66
Revenue per share
$0.45
TBVPS
$2.67
Balance sheet
Total assets
$89.55M
Total liabilities
$63.02M
Debt
$3.12M
Equity
$26.53M
Working capital
$64.56M
Liquidity
Debt to equity
0.12
Current ratio
5.06
Quick ratio
4.88
Net debt/EBITDA
0.92
Margins
EBITDA margin
-539.9%
Gross margin
100%
Net margin
-582.3%
Operating margin
-594.8%
Efficiency
Return on assets
-71.6%
Return on equity
-154%
Return on invested capital
-265.5%
Return on capital employed
-120.6%
Return on sales
-595.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CARM stock price

How has the Carisma Therapeutics stock price performed over time
Intraday
1.25%
1 week
-1.22%
1 month
-17.77%
1 year
-66.11%
YTD
-44.71%
QTD
-28.63%

Financial performance

How have Carisma Therapeutics's revenue and profit performed over time
Revenue
$14.92M
Gross profit
$14.92M
Operating income
-$88.73M
Net income
-$86.88M
Gross margin
100%
Net margin
-582.3%
The company's operating income has shrunk by 58% YoY and by 9% QoQ
The company's revenue has surged by 52% YoY and by 3.9% QoQ
CARM's gross profit has surged by 52% year-on-year and by 3.9% since the previous quarter
The net income has declined by 42% year-on-year and by 5% since the previous quarter

Growth

What is Carisma Therapeutics's growth rate over time

Valuation

What is Carisma Therapeutics stock price valuation
P/E
N/A
P/B
2.46
P/S
3.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.48
The company's EPS has surged by 91% YoY and by 76% QoQ
The equity has soared by 117% YoY but it is down by 43% QoQ
The P/B is 30% less than the last 4 quarters average of 3.5
The price to sales (P/S) is 70% lower than the last 4 quarters average of 12.2
The company's revenue has surged by 52% YoY and by 3.9% QoQ

Efficiency

How efficient is Carisma Therapeutics business performance
The return on invested capital has dropped by 190% year-on-year and by 64% since the previous quarter
The return on equity has dropped by 103% year-on-year but it has surged by 80% since the previous quarter
CARM's ROA has dropped by 97% year-on-year
The company's return on sales fell by 4% QoQ

Dividends

What is CARM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CARM.

Financial health

How did Carisma Therapeutics financials performed over time
Carisma Therapeutics's total assets is 42% higher than its total liabilities
Carisma Therapeutics's quick ratio has soared by 85% YoY but it has decreased by 33% from the previous quarter
Carisma Therapeutics's current ratio has surged by 82% YoY but it has decreased by 33% QoQ
The debt is 88% less than the equity
CARM's debt to equity has soared by 146% YoY and by 100% QoQ
The equity has soared by 117% YoY but it is down by 43% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.